FDMT - 4D Molecular slips after regulatory update on lead asset
2024-03-28 10:43:38 ET
More on 4D Molecular Therapeutics
- 4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
- 4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
- Goldman reinstates buy rating on 4D Molecular, cites upcoming catalysts
- 4D Molecular Therapeutics up 3%, prices $300M equity
- Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics